Recent advances in Point of care testing for infectious diseases
Pathogenic microorganisms cause infectious diseases, which can be spread between individuals and populations, posing a threat to public health and potentially the economy. To provide accurate and timely guidance for case identification, transmission interruption, and proper treatment administration, effective diagnostic tools are required. Point of Care (POC) testing for infectious diseases have actionable results close to the patient and therefore function as a personal "radar."
Comparing various molecular methods, such as pathogen nucleic acid and protein, circulating microRNA, and antibodies, used in POC tests for several major pathogens, including malaria parasites, human immunodeficiency virus (HIV), human papillomavirus (HPV), dengue, Ebola, and Zika viruses, and Mycobacterium tuberculosis (TB), can be performed for several major pathogens, including malaria parasites, human immune Recent developments in novel POC technology, such as microfluidic and plasmonic-based approaches, are the subject of such approaches.
When it comes to designing medical instruments for diagnosis at the point of treatment, optical imaging methods provide a range of significant advantages. In modern point-of-care optics design for infectious disease research, optical imaging can provide real-time and high-resolution microscopic and macroscopic information leading to a rapid and accurate diagnosis.
POC is described as the administration of a test whose outcome will be used to make a quick decision and take appropriate action, resulting in a better health outcome within the same encounter. POC's main goal is to achieve a result more quickly, especially in treating infectious diseases. Point-of-care diagnostics for infectious diseases has been a rapidly growing research sector for years. Prior to COVID-19, the compound annual growth rate (CAGR) of POC testing for infectious diseases was projected to be about 10.3% over the forecast period. Post COVID-19, this is likely to be an order of magnitude higher with every biotech industry, government, and academic institute scrambling to develop rapid, accurate diagnostic tools to detect and monitor the transmission of SARS CoV-2.
